Resverlogix Corp. (TSE:RVX – Get Free Report) traded up 23.1% during trading on Thursday . The stock traded as high as C$0.08 and last traded at C$0.08. 252,786 shares were traded during trading, an increase of 554% from the average session volume of 38,672 shares. The stock had previously closed at C$0.07.
Resverlogix Stock Performance
The company’s 50-day moving average price is C$0.05 and its 200-day moving average price is C$0.06. The firm has a market capitalization of C$20.61 million, a PE ratio of -1.30 and a beta of 0.71.
Resverlogix Company Profile
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases.
Featured Articles
- Five stocks we like better than Resverlogix
- How to Invest in Blue Chip Stocks
- Michael Burry’s Alibaba Bet and the Broader Market Implications
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Jeff Brown’s Exegesis AI Stock Picks
- What Are Dividends? Buy the Best Dividend Stocks
- Warren Buffett’s Bet: Why Berkshire Hathaway Bought Ulta Stock
Receive News & Ratings for Resverlogix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Resverlogix and related companies with MarketBeat.com's FREE daily email newsletter.
